Ambrx Biopharma Inc.
AMAMNYSEHealthcare
$28.00
+$0.02(+0.07%)
Market Cap$1.8B
P/E Ratio—
52W High$28.15
52W Low$6.55
Ambrx Biopharma Inc. (AMAM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMAM · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | ($78.00M) | ($68.29M) | ($17.84M) | ($22.31M) |
| Depreciation & Amort. | $1.80M | $2.15M | $1.94M | $2.05M |
| Stock-Based Comp. | $6.25M | $11.86M | $1.22M | $1.83M |
| Change in Working Capital | ($10.62M) | $3.64M | ($7.38M) | $14.18M |
| Net Cash from Operations | ($68.67M) | ($44.64M) | ($20.58M) | ($2.77M) |
| Investing Activities | ||||
| Capital Expenditure | ($1.05M) | ($3.21M) | ($0.25M) | ($0.05M) |
| Purchases of Investments | ($84.85M) | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $39.19M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($46.72M) | ($3.21M) | ($0.25M) | ($0.05M) |
| Financing Activities | ||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $0.93M | $127.43M | $95.68M | $0.00M |
| Free Cash Flow | ||||
| Free Cash Flow | ($69.73M) | ($47.85M) | ($20.83M) | ($2.81M) |
| FCF Margin %(computed) | -942.03% | -641.80% | -152.35% | -27.28% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Ambrx Biopharma Inc. data
About Ambrx Biopharma Inc. (AMAM) Cash Flow Statement
Ambrx Biopharma Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.07B) for 2022 — a FCF margin of -942.03%. Capital expenditure was ($0.00B).
Frequently asked questions
AMAM · 4 questionsAmbrx Biopharma Inc. generated free cash flow of ($0.07B) for 2022, down 45.7% year-over-year.
AMAM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10